#United States #Class Action #Philadelphia #Berger Montague #MoonLake

Berger Montague Files Class Action Against MoonLake Immunotherapeutics

In a pivotal move for investors, Berger Montague PC, a national plaintiffs' law firm, has announced a class action lawsuit against MoonLake Immunotherapeutics, a clinical-stage biotech firm listed on NASDAQ under the ticker MLTX. The firm has called upon investors who purchased shares of MoonLake during the period from March 10, 2024, to September 29, 2025, to consider joining the lawsuit. The deadline for potential lead plaintiffs to step forward is December 15, 2025.

Background on MoonLake Immunotherapeutics

MoonLake, headquartered in Zug, Switzerland, focuses on developing next-generation immunotherapies to combat various diseases. Central to their portfolio is sonelokimab (SLK), a drug candidate promoted as a groundbreaking treatment based on its unique Nanobody structure. However, the lawsuit alleges that the company misled its investors by failing to fully disclose critical information regarding SLK’s efficacy compared to existing treatments.

Allegations and Efficacy Concerns

The crux of the complaint asserts that SLK targets the same molecules as BIMZELX, a monoclonal antibody already approved by the FDA. This revelation raises serious questions about SLK’s claimed superiority and market potential. On September 28, 2025, MoonLake disclosed the results of a Phase 3 trial for SLK, which reportedly did not meet the anticipated efficacy benchmarks. Analysts characterized these results as